Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors

Standard

Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. / Kalinin, Stanislav; Malkova, Anna; Sharonova, Tatiana ; Sharoyko, Vladimir; Bunev, Alexander; Supuran, Claudiu T.; Krasavin, Mikhail.

In: International Journal of Molecular Sciences, Vol. 22, No. 24, 13405, 14.12.2021.

Research output: Contribution to journal › Review article › peer-review

BibTeX

@article{c67e5654dc4441e88bf2ea7f1578a491,

title = "Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors",

abstract = "Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.",

keywords = "Adjuvant agents, Carbonic anhydrase IX, Small-molecule inhibitors, Solid tumors, Tumor acidosis combination cancer therapy, Tumor hypoxia",

author = "Stanislav Kalinin and Anna Malkova and Tatiana Sharonova and Vladimir Sharoyko and Alexander Bunev and Supuran, {Claudiu T.} and Mikhail Krasavin",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = dec,

day = "14",

doi = "10.3390/ijms222413405",

language = "English",

volume = "22",

journal = "International Journal of Molecular Sciences",

issn = "1422-0067",

publisher = "MDPI AG",

number = "24",

}

RIS

TY - JOUR

T1 - Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors

AU - Kalinin, Stanislav

AU - Malkova, Anna

AU - Sharonova, Tatiana

AU - Sharoyko, Vladimir

AU - Bunev, Alexander

AU - Supuran, Claudiu T.

AU - Krasavin, Mikhail

PY - 2021/12/14

Y1 - 2021/12/14

N2 - Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.

AB - Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.

KW - Adjuvant agents

KW - Carbonic anhydrase IX

KW - Small-molecule inhibitors

KW - Solid tumors

KW - Tumor acidosis combination cancer therapy

KW - Tumor hypoxia

UR - http://www.scopus.com/inward/record.url?scp=85121334761&partnerID=8YFLogxK

U2 - 10.3390/ijms222413405

DO - 10.3390/ijms222413405

M3 - Review article

AN - SCOPUS:85121334761

VL - 22

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1422-0067

IS - 24

M1 - 13405

ER -

ID: 90454425